Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Receivables (2016 - 2025)

Historic Receivables for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $14.4 million.

  • Protalix BioTherapeutics' Receivables rose 55717.54% to $14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.4 million, marking a year-over-year increase of 55717.54%. This contributed to the annual value of $2.9 million for FY2024, which is 4482.17% down from last year.
  • According to the latest figures from Q3 2025, Protalix BioTherapeutics' Receivables is $14.4 million, which was up 55717.54% from $9.4 million recorded in Q2 2025.
  • Over the past 5 years, Protalix BioTherapeutics' Receivables peaked at $14.4 million during Q3 2025, and registered a low of $1.3 million during Q1 2023.
  • Moreover, its 5-year median value for Receivables was $4.6 million (2021), whereas its average is $5.5 million.
  • Its Receivables has fluctuated over the past 5 years, first tumbled by 7792.82% in 2023, then soared by 55717.54% in 2025.
  • Protalix BioTherapeutics' Receivables (Quarter) stood at $3.4 million in 2021, then surged by 33.24% to $4.6 million in 2022, then increased by 14.96% to $5.3 million in 2023, then crashed by 44.82% to $2.9 million in 2024, then soared by 395.87% to $14.4 million in 2025.
  • Its Receivables was $14.4 million in Q3 2025, compared to $9.4 million in Q2 2025 and $4.7 million in Q1 2025.